Search

Your search keyword '"Vilaseca P"' showing total 419 results
Start Over Author "Vilaseca P" Database Supplemental Index
419 results on '"Vilaseca P"'

2. HARMONI at ELT: calibration module functional and design description

Author

Bryant, Julia J., Motohara, Kentaro, Vernet, Joël R. D., Argelaguet Vilaseca, Heribert, Piqueras López, Javier, Estrada Piqueras, Alberto, Alvarez Ureña, Alonso, Ferro, Irene, Carracedo Carballal, Gonzalo, Arribas, Santiago, Pereira-Santaella, Miguel, Fernandez Rodriguez, Marianela, and Schwartz, Noah

Published
2024
Full Text
View/download PDF

3. What is a liveable tourist city in twenty-first-century Spain? From leisure and consumption to degrowth

Author

Vilaseca, Stephen Luis

Abstract

This editorial raises crucial issues surrounding the sustainability of tourist cities in Spain, highlighting the tension between the desire for leisure and consumption-driven tourism and the growing need for more sustainable, degrowth-oriented practices. Through the lens of philosopher Marina Garcés’s concept of liveability, it explores the challenges and potential solutions for creating tourist cities in Spain that are not only attractive and liveable but also environmentally responsible and socially equitable.

Published
2024
Full Text
View/download PDF

4. Urine-based testing for patient selection and genomic characterization of patients with FGFR alteration-positive non–muscle-invasive bladder cancer (NMIBC) treated with TAR-210.

Author

Li, Roger, Ku, Ja Hyeon, Vilaseca Cabo, Antoni, Guerrero-Ramos, Félix, Meeks, Joshua J, Beeharry, Neil, Quiroz, Michelle, Zhang, Jiarui, Smirnov, Denis, Rajpurohit, Yashoda Rani, Brunton, Bethany, Martinez, Gabriela, Cost, Carrye Rudolph, Kalota, Anna, Lauring, Josh David, Stone, Nicole L., Thomas, Shibu, Jia, Shidong, Kim, Il-Jin, and Du, Pan

Published
2024
Full Text
View/download PDF

5. Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis

Author

Fissolo, Nicolás, Benkert, Pascal, Sastre-Garriga, Jaume, Mongay-Ochoa, Neus, Vilaseca-Jolonch, Andreu, Llufriu, Sara, Blanco, Yolanda, Hegen, Harald, Berek, Klaus, Perez-Miralles, Francisco, Rejdak, Konrad, Villar, Luisa M, Monreal, Enric, Alvarez-Lafuente, Roberto, Soylu, Onder K, Abdelhak, Ahmed, Bachhuber, Franziska, Tumani, Hayrettin, Martínez-Yélamos, Sergio, Sánchez-López, Antonio J, García-Merino, Antonio, Gutiérrez, Lucía, Castillo-Trivino, Tamara, Lycke, Jan, Rosenstein, Igal, Furlan, Roberto, Filippi, Massimo, Téllez, Nieves, Ramió-Torrentà, Lluís, Lu¨nemann, Jan D, Wiendl, Heinz, Eichau, Sara, Khalil, Michael, Kuhle, Jens, Montalban, Xavier, and Comabella, Manuel

Abstract

BackgroundWe aimed to investigate the potential of serum biomarker levels to predict disability progression in a multicentric real-world cohort of patients with primary progressive multiple sclerosis (PPMS).MethodsA total of 141 patients with PPMS from 18 European MS centres were included. Disability progression was investigated using change in Expanded Disability Status Scale (EDSS) score over three time intervals: baseline to 2 years, 6 years and to the last follow-up. Serum levels of neurofilament light chain (sNfL), glial fibrillar acidic protein (sGFAP) and chitinase 3-like 1 (sCHI3L1) were measured using single-molecule array assays at baseline. Correlations between biomarker levels, and between biomarkers and age were quantified using Spearman’s r. Univariable and multivariable linear models were performed to assess associations between biomarker levels and EDSS change over the different time periods.ResultsMedian (IQR) age of patients was 52.9 (46.4–58.5) years, and 58 (41.1%) were men. Median follow-up time was 9.1 (7.0–12.6) years. Only 8 (5.7%) patients received treatment during follow-up. sNfL and sGFAP levels were moderately correlated (r=0.43) and both weakly correlated with sCHI3L1 levels (r=0.19 and r=0.17, respectively). In multivariable analyses, levels of the three biomarkers were associated with EDSS changes across all time periods. However, when analysis was restricted to non-inflammatory patients according to clinical and radiological parameters (n=64), only sCHI3L1 levels remained associated with future EDSS change.ConclusionsLevels of sNfL, sGFAP and sCHI3L1 are prognostic biomarkers associated with disability progression in patients with PPMS, being CHI3L1 findings less dependent on the inflammatory component associated with disease progression.

Published
2024
Full Text
View/download PDF

6. Early Identification and Management of Patients with Rash on Apalutamide

Author

Birtle, Alison J., Formisano, Luigi, Descamps, Vincent, Weisenseel, Peter, and Vilaseca, Antoni

Abstract

Apalutamide is a selective androgen receptor signalling inhibitor that is used in the treatment of prostate cancer. Skin rash is one of the most common adverse events with apalutamide. Although the majority of rash events are grade 1 and 2, the appearance of skin rash during treatment can lead to dose reduction, a pause in treatment or even treatment discontinuation, especially if patients present late when the rash has become severe. This in turn can result in a significant delay or even a permanent discontinuation in the patient’s treatment of prostate cancer. As apalutamide is a generally well tolerated and an effective treatment for many men with advanced prostate cancer, it is extremely important to make attempts to prevent skin problems or to manage them at the earliest stage possible. We therefore have developed practical guidance for the management of apalutamide-related rash, including an infographic with recommendations for rash management by grade. Central to this approach is patient education and awareness. Encouraging patients to proactively care for their skin from the start of treatment and informing them of the risk of rash with apalutamide therapy are essential. If the patient observes any skin changes, they should be advised to report it straight away to their cancer care team. Adopting this simple, proactive approach of patient education and increased vigilance from the care team is expected to lead to early identification of rash and subsequent intervention to allow for quicker resolution and enable patients to continue their cancer treatment with a drug that can delay disease progression and increase survival in patients with prostate cancer.

Published
2024
Full Text
View/download PDF

7. Article: Pillar I: The Marketing and Distribution Safe Harbour (MDSH) as Applicable to Licensed Manufacturers and Centralized Business Models: Does It Fulfil Its Policy Objective? [pre-publication]

Author

Vilaseca, Camille and Chand, Vikram

Abstract

The new Pillar I Amount A system aims to reallocate a portion of in-scope MNEs’ residual profits to market countries. This said, there could be many instances when an MNE already reports residual profits in the market country under the current system, for example, when it operates with a substantial physical presence (which is entrepreneurial in nature) in the market country. In order to avoid the double taxation/double counting of what is known as ‘residual profits’, a Marketing and Distribution Safe Harbour (MDSH) mechanism was first developed in the 2020 Blueprint and redesigned in the 2022 Progress Report. The purpose of this article is to address the question as to whether the MDSH as designed in the Progress Report meets its objective, particularly after briefly describing it as drafted in both reports. The authors analyse whether it does so by testing it against two commonly found MNE business models, i.e., a licensed manufacturer (LM) in the market and a centralized business model with limited risk distributors (LRD) in the market. A technical analysis is undertaken which is then illustrated with numerical case studies. The analysis leads to the conclusion that the MDSH as designed in the Progress Report does not necessarily meet its policy objective of preventing double counting under both the LM and the centralized business models. Thus, one possible policy option is to redraft it and return to the test as originally conceived in the Blueprint. A second possibility is to further reflect on some of the MDSH components, in particular, the manner in which jurisdictional routine and residual profits are calculated with the overall aim of achieving simplicity as well as accuracy. With respect to determining jurisdictional routine profits, our main recommendation is to deem a certain percentage of jurisdictional elimination profits (EPs) to represent routine profits (e.g., 25%). Such a mechanism would be simpler than the existing mechanism to determine jurisdictional routine profits, which seems to be rather complicated. With respect to jurisdictional residual profits, our recommendation is to support the Y% with a facts and circumstances analysis to achieve accurate results (at least, in certain cases). For instance, the Y% will be deemed to be 100% in a country when the MNE group operates with a fully or partly decentralized business model such as a LM (or similar business models such as franchise models). It will be regarded as being 0% in a country when it operates with limited risk sales structures or/and structures that have access to the simplification offered by the Amount B project. In all other cases, the Y% could be considered to be, for example, 25% in a country (which would be a compromise). Moreover, our recommendation with respect to withholding taxes (WHT) (if they are taken into account) is to restrict its scope to selected payments (e.g., royalties or service fees) and to provide a downward adjustment in the residence jurisdiction of the recipient (as opposed to the payors). The effect would be that the EP of the recipient would be reduced, and these profits would then represent the base to provide relief from double taxation. More broadly, if the Amount A project does not achieve fruition, the authors believe that some lessons that can be learned from the Amount A reform, in general, and the MDSH for future alternate reforms. Thus, a few suggestions will be made to policymakers who are considering alternatives to the Amount A project.

Published
2023

8. Pillar I: The Marketing and Distribution Safe Harbour (MDSH) as Applicable to Licensed Manufacturers and Centralized Business Models: Does It Fulfil Its Policy Objective?

Author

Vilaseca, Camille and Chand, Vikram

Abstract

The new Pillar I Amount A system aims to reallocate a portion of in-scope MNEs’ residual profits to market countries. This said, there could be many instances when an MNE already reports residual profits in the market country under the current system, for example, when it operates with a substantial physical presence (which is entrepreneurial in nature) in the market country. In order to avoid the double taxation/double counting of what is known as ‘residual profits’, a Marketing and Distribution Safe Harbour (MDSH) mechanism was first developed in the 2020 Blueprint and redesigned in the 2022 Progress Report. The purpose of this article is to address the question as to whether the MDSH as designed in the Progress Report meets its objective, particularly after briefly describing it as drafted in both reports. The authors analyse whether it does so by testing it against two commonly found MNE business models, i.e., a licensed manufacturer (LM) in the market and a centralized business model with limited risk distributors (LRD) in the market. A technical analysis is undertaken which is then illustrated with numerical case studies. The analysis leads to the conclusion that the MDSH as designed in the Progress Report does not necessarily meet its policy objective of preventing double counting under both the LM and the centralized business models. Thus, one possible policy option is to redraft it and return to the test as originally conceived in the Blueprint. A second possibility is to further reflect on some of the MDSH components, in particular, the manner in which jurisdictional routine and residual profits are calculated with the overall aim of achieving simplicity as well as accuracy. With respect to determining jurisdictional routine profits, our main recommendation is to deem a certain percentage of jurisdictional elimination profits (EPs) to represent routine profits (e.g., 25%). Such a mechanism would be simpler than the existing mechanism to determine jurisdictional routine profits, which seems to be rather complicated. With respect to jurisdictional residual profits, our recommendation is to support the Y% with a facts and circumstances analysis to achieve accurate results (at least, in certain cases). For instance, the Y% will be deemed to be 100% in a country when the MNE group operates with a fully or partly decentralized business model such as a LM (or similar business models such as franchise models). It will be regarded as being 0% in a country when it operates with limited risk sales structures or/and structures that have access to the simplification offered by the Amount B project. In all other cases, the Y% could be considered to be, for example, 25% in a country (which would be a compromise). Moreover, our recommendation with respect to withholding taxes (WHT) (if they are taken into account) is to restrict its scope to selected payments (e.g., royalties or service fees) and to provide a downward adjustment in the residence jurisdiction of the recipient (as opposed to the payors). The effect would be that the EP of the recipient would be reduced, and these profits would then represent the base to provide relief from double taxation. More broadly, if the Amount A project does not achieve fruition, the authors believe that some lessons that can be learned from the Amount A reform, in general, and the MDSH for future alternate reforms. Thus, a few suggestions will be made to policymakers who are considering alternatives to the Amount A project.

Published
2023

9. Simulación del proceso precipitación-escorrentía con paso diario: comparación de los modelos GR4J, SWAT y random forest

Author

Vilaseca, Federico, Narbondo, Santiago, Chreties, Christian, Castro, Alberto, and Gorgoglione, Angela

Abstract

RESUMENUn sólido estudio hidrológico diario es una tarea desafiante en regiones caracterizadas por una alta variabilidad hidro-climática, como Uruguay. Por esta razón, los modelos hidrológicos de base física de diferentes escalas temporales y espaciales (concentrados, semi-distribuidos y distribuidos) han pasado por un largo período de desarrollo y aplicación local. En los últimos años, los modelos basados en datos se están usando con éxito para resolver problemas hidrológicos. Hasta ahora, estos diferentes tipos de modelos se han estudiado individualmente para evaluar su capacidad para simular el proceso diario de precipitación-escorrentía. Este trabajo proporciona una profunda comparación entre un modelo agregado (GR4J), un modelo semi-distribuido (SWAT) y otro basado en datos (Random Forest (RF)) para simular el proceso diario de precipitación-escorrentía de dos cuencas hidrográficas ubicadas en Uruguay (una con reservorio y la otra sin). El rendimiento de cada modelo se analizó comparando numéricamente y gráficamente el caudal observado versus el simulado en términos de correspondencia temporal y cuantiles. En general, RF presenta un mejor rendimiento en comparación con los otros modelos físicamente basados. Sin embargo, carece de la capacidad de generalización que caracterizó a los otros dos enfoques. GR4J y SWAT logran un desempeño similar en nuestros casos de estudio.

Published
2023
Full Text
View/download PDF

10. Experimental validation of ball burnishing numerical simulation on ball-end milled martensitic stainless-steel considering friction and the initial surface topography

Author

Torres, Alejandra, Amini, Cyrus, Cuadrado, Nuria, Travieso-Rodriguez, J. Antonio, Llumà, Jordi, and Vilaseca, Montserrat

Abstract

Numerous simplified numerical models have been established to optimize the ball burnishing of steel surfaces. Nevertheless, their conceptualization has not considered the tool–part interaction, leading to an unsatisfactory process parameterization. As a solution, a structured numerical simulation has been defined that reproduces this interaction by several friction coefficient approximations. This study provides the tribological process inputs (friction and initial surface conditions) to this model, adapting it to a pre-textured martensitic precipitation hardening stainless-steel. Results show the versatility of the model to reproduce the surface integrity alterations. Hence, this consistent model configuration can be postulated as an economical and efficient approach to tackle ball burnishing parameterization according to the applicability of the manufactured steel parts.

Published
2023
Full Text
View/download PDF

11. Evaluating the cost-utility of a direct transfer to angiosuite protocol within 6 h of symptom onset in suspected large vessel occlusion patients

Author

Requena, Manuel, Seguel-Ravest, Valeska, Vilaseca-Jolonch, Andreu, Woods, Jacklyn, Guijarro, Pablo, Ribo, Marc, Tomasello, Alejandro, and Molina, Carlos A.

Abstract

AbstractIntroductionA direct transfer to angiosuite (DTAS) protocol has shown to be effective and safe by shortening in-hospital workflows and encouraging long-term outcome benefits. To implement DTAS at a new facility, a large organizational effort is necessary. We performed a cost-utility analysis and budget impact analysis (BIA) of the operation of a new angiosuite, primarily dedicated to stroke patients, that allows facilities to approximate the cost implications of utilizing a DTAS pathway.MethodsSixty-one patients who underwent endovascular treatment (EVT) following DTAS were matched for baseline variables to 117 patients who underwent a conventional imaging protocol at a hospital in Catalonia, Spain. An economic model, based on actual data from these patients, was developed to assess the short- and long-term clinical and economic implications of DTAS. In the BIA, the DTAS scenario was gradually implemented for 20% of patients each year until reaching a plateau at 80% of patients in the DTAS pathway. Initial investment and additional organizational costs, €4 million, were taken into consideration to compare the budget impact of the DTAS scenario with no organizational changes over five years.ResultsDTAS was associated with better patient functional independence rates (mRS 0–2: 50.9% vs. 41.0%) and a quality-adjusted life-years gain of 0.82 per patient. Despite the additional initial investment, DTAS development was associated with an estimated 10.2% reduction (€14.7 million) of the total costs (€144.5 million). Cost savings were mainly due to long-term associated costs related to patient disability (€13.2 million).LimitationsThe study relies on data obtained from a single-center, and therefore it may be difficult to generalize the findingsConclusionsOur economic model predicts that the implementation of a DTAS program is cost-effective compared with no organizational changes. Our model also predicts better clinical outcomes for patients in terms of functional independence and quality-adjusted life years.

Published
2022
Full Text
View/download PDF

12. Why should speech-language pathologists read graphic novels? A commentary on humanities as a pathway to improving patient-centred care

Author

Knudson-Vilaseca, Emily

Abstract

Like all who work in medical or allied health professions, speech-language pathologists would benefit from supplementing their learning with humanities education, as it can help to improve diagnostic skills and to develop empathy. Graphic novels on illness and disease, conceived of by those in the medical humanities as “graphic medicine,” have an appeal for their brevity and association with humour, and for their ability to express complex thoughts and feelings through a medium that is both visual and literary. As such, they serve as an ideal resource for deepening one’s understanding of how disorders and diseases are experienced by patients and their caregivers and for helping student clinicians, therapists, and researchers recognize their shared humanity with patients and study participants. In this article, I expand on these ideas and, in order to demonstrate the benefit of closely reading graphic novels from a speech-pathology perspective, I offer my own analysis of Tangles: A Story of Alzheimer’s, My Mother, and Meby Sarah Leavitt (2012).

Published
2022
Full Text
View/download PDF

13. Effect of Positive Surgical Margins in Patients Who Undergo a Partial Nephrectomy Regarding Recurrence, Overall Survival, Recurrence/Progression-Free Survival, and Metastasis-Free Survival. A Systematic Review and Meta-Analysis

Author

García-Perdomo, Herney Andrés, Ribal Caparrós, Maria Jose, Alcaraz Asensio, Antonio, and Vilaseca Cabo, Antoni

Abstract

To determine the effect of positive surgical margins in patients who undergo a partial nephrectomy regarding recurrence, overall survival, disease-free survival, recurrence and progression-free survival, and metastasis-free survival.

Published
2022
Full Text
View/download PDF

14. Transcriptome wide correlations with neuropathological hallmarks in the frontal cortex of FTLD patients.

Author

Dols‐Icardo, Oriol, Dolcet, Sònia Sirisi, Montal, Victor, Molina, Laura, Naganathan, Vikram, Querol‐Vilaseca, Marta, Illán‐Gala, Ignacio, Pegueroles, Jordi, Tamayo, Natalia Valle, Sánchez‐Aced, Érika, Cervantes‐González, Alba, Iulita, M. Florencia, Belbin, Olivia, Blesa, Rafael, Fortea, Juan, Lleó, Alberto, and Clarimón, Jordi

Abstract

Background: A key pathological event in frontotemporal lobar degeneration (FTLD) is the alteration of the RNA metabolism. Despite this, no study has characterized the diversity of RNA species using high‐throughput sequencing approaches and correlated them with the main neuropathological hallmarks across FTLD subtypes. Method: Total and small RNA sequencing was performed in the frontal cortex of patients neuropathologically diagnosed with FTLD‐TDP (including non‐mutation carriers [sFTLD‐TDP;n = 9], and carriers of the C9orf72 repeat expansion [FTLD‐C9;n = 11]), FTLD‐tau (n = 13, six carrying the p.P301L mutation in MAPT) and controls without neuropathological alterations in the same brain region (n = 7). Gene and miRNA co‐expression modules were identified using WGCNA. Cell‐type proportions were estimated through cell‐type deconvolution using MuSiC. Gene ontology enrichment analyses were performed using Metascape. We assessed in the frontal cortex the presence of pTDP43 (in sFTLD‐TDP and FTLD‐C9), dipeptide repeats and RNA foci (in FTLD‐C9), and tau aggregates (in FTLD‐tau) through quantitative immunohistochemistry and correlated their density with transcriptome‐wide RNA alterations. Result: Our results indicate statistically significant correlations between gene and miRNA co‐expression modules, neuropathological changes and cell‐type proportions specific for each FTLD subtype. The most significant findings include: in sFTLD‐TDP, the density of pTDP43 positively correlated with a gene co‐expression module (R = 0.9,p = 0.04) enriched with splicing functions (p<1×10−8), which directly correlated with a miRNA co‐expression module (R = 0.77,p = 5×10−4) and the proportion of a microglial subpopulation (R = 0.69,p = 4×10−3). In FTLD‐C9, the density of poly(GP) repeats inversely correlated with the proportion of a neuronal subpopulation (R = ‐0.62,p = 0.041), and negatively correlated with a gene co‐expression module (R = ‐0.67,p = 0.024) enriched with protein phosphorylation functions (p<1×10−4). In FTLD‐tau, the density of tau aggregates negatively correlated with the proportion of a neuronal subpopulation (Fig.1A;R = ‐0.77,p = 0.003) and positively correlated with a miRNA (Fig.1B;R = 0.88,p = 8.8×10−5) and a gene (Fig.1C;R = 0.65,p = 0.016) co‐expression module enriched in genes with neuron ensheathing functions (Fig.1D;p<1×10−20). Conclusion: Our data demonstrate selective vulnerability of cell‐subtypes to neuropathological changes. In addition, we describe striking correlations between the main neuropathological hallmarks of each FTLD subtype and specific gene and miRNA co‐expression modules, including their hub genes and miRNAs which might be used as biomarkers to identify the FTLD neuropathological substrate in vivo, and reveal novel molecular mechanisms amenable for therapeutic intervention in FTLD. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

16. Fue un accidente.

Author

Vilaseca Llobet, Josep Maria

Abstract

Copyright of AMF: Actualización en Medicina de Familia is the property of Sociedad Espanola de Medicina en Familia y Comunitaria and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2024
Full Text
View/download PDF

17. HARMONI at ELT: project status and instrument overview

Author

Bryant, Julia J., Motohara, Kentaro, Vernet, Joël R. D., Thatte, Niranjan A., Melotte, Dave, Neichel, Benoit, Le Mignant, David, Rees, Phil, Clarke, Fraser, Ferraro-Wood, Vanessa, Gonzalez, Oscar, Jones, Maia, Álvarez Urueña, Alonso, Argelaguet Vilaseca, Heribert, Arribas Mocoroa, Santiago, Caballero, José Antonio, Carracedo Carballal, Gonzalo José, Estrada Piqueras, Alberto, Ferro, Irene, García García, Miriam, Lamperti, Isabella, Pereira Santaella, Miguel, Perna, Michele, Piqueras Lopez, Javier, Bouché, Nicolas, Boudon, Didier, Daguise, Eric, Domenis, Nicola, Fensch, Jérémy, Olivier Flasseur, Olivier, Giroud, Rémi, Guibert, Matthieu, Jarno, Aurelien, Jeanneau, Alexandre, Krogager, Jens-Kristian, Langlois, Maud, Laurent, Florence, Loupias, Magali, Migniau, Jean-Emmanuel, Nguyen, Dieu, Piqueras, Laure, Remillieux, Alban, Richard, Johan, Pecontal, Arlette, Bardou, Lisa, Barr, David, Cetre, Sylvain, Dimoudi, Sofia, Dubbeldam, Marc, Dunn, Andrew, Gadotti, Dimitri, Guy, Joss, King, David, McLeod, Anna, Morris, Simon, Morris, Tim, O'Brien, Kieran, Ronson, Emily, Smith, Russell, Staykov, Lazar, Swinbank, Mark, Accardo, Matteo, Alvarez Mendez, Domingo, Fuerte Rodriguez, Pablo Alberto, George, Elizabeth, Ives, Derek, Mehrgan, Leander, Mueller, Eric, Reyes, Javier, Conzelmann, Ralf, Gutierrez Cheetham, Pablo, Alonso Sanchez, Angel, Battaglia, Giuseppina, Cagigas, Miguel, Castro-Almazán, Julio A., Chulani, Haresh, Delgado-García, Graciela, Fernandez Izquierdo, Patricia, Esparza-Arredondo, Donaji, García-Lorenzo, Begoña, Hernández González, Alberto, Hernández Suárez, Elvio, Licandro, Javier, Joven, Enrique, López López, Roberto, Lujan Gonzalez, Alejandro Antonio, Martín Hernando, Yolanda, Martín-Navarro, Ignacio, Mediavilla, Evencio, Menéndez Mendoza, Saúl, Montoya Martínez, Luz Maria, Peñate Castro, José, Murgas, Felipe, Pallé, Enric, Pérez, Álvaro, Rasilla, Jose Luis, Rebolo, Rafael, Rodríguez, Horacio, Rodríguez Ramos, Luis Fernando, Sánchez Béjar, Victor, Shahbaz, Tariq, Vega Moreno, Afrodisio, Viera, Teodora, Bonnefoy, Mickaël, Bret, Tony, Carlotti, Alexis, Correia, Jean-Jacques, Curaba, Stéphane, Delboulbé, Alain, Guieu, Sylvain, Hours, Adrien, Hubert, Zoltan, Jocou, Laurent, Magnard, Yves, Michaud, Laurence, Moulin, Thibaut, Pancher, Fabrice, Rabou, Patrick, Rochat, Sylvain, Stadler, Eric, Contini, Thierry, Larrieu, Marie, Mamessier, Sébastien, Boebion, Olivier, Fantei-Caujolle, Yan, Lecron, Daniel, Amram, Philippe, Blanchard, Patrick, Bon, William, Bonnefoi, Anne, Bozier, Alexandre, Ceria, William, Challita, Zalpha, Charles, Yannick, Choquet, Elodie, Costille, Anne, Delsanti, Audrey, Dohlen, Kjetil, Ducret, Franck, El Hadi, Kacem, Foulon, Benjamin, Gimenez, Jean-Luc, Groussin, Olivier, Jaquet, Marc, Renault, Edgard, Rouquette, Paul, Sanchez, Patrice, Vigan, Arthur, Zavagno, Annie, Fétick, Romain, Fusco, Thierry, Héritier, Cedric, Sauvage, Jean-Francois, Vedrenne, Nicolas, Aksoy, Demet, Caldwell, Martin, Fitzpatrick, Ann, Geddert, Carl, Hiscock, Peter, Johnson, Emma, Nalagatla, Murali, Saraff, Louise, Shreeves, Joe, Tildesley, Matthew, Wells, Mark, Aretos, Anastasios, Barrett, Lee, Black, Martin, Bond, Charlotte, Brierley, Saskia, Bryson, Ian, Calderhead, Amelia, Campbell, Kenny, Carruthers, James, Chapman, Lee, Cochrane, William, Gillespie, Rory, Harman, Joel, Harvey, Douglas, Harvey, Eamonn, Johnson, Bethany, Louth, Tom, MacIntosh, Mike, MacIver, Anna, Miller, Chris, Montgomery, David, Murali, Meenu, Murray, John, O'Malley, Norman, Sanchez-Janssen, Ruben, Schwartz, Noah, Smith, Patrick, Strachan, Jonathan, Todd, Stephen, Wasley, Dawn, Wilson, Sandi, Zhou, Junyi, Bell, Eric, Gnedin, Oleg, Gultekin, Kayhan, Mateo, Mario, Meyer, Michael, Birkby, Jayne, Boland, Liam, Cappellari, Michele, Castillo Dominguez, Edgar, Gooding, David, Grisdale, Kearn, Hidalgo, Andrea, Kariuki, James, Lewis, Ian, McCall, Kieran, Meyer, R. Elliot, Muslimov, Eduard, Lowe, Adam, Ozer, Zeynep, Paszynska, Sophie, Rigopoulou, Dimitra, Tecza, Matthias, and York, Alec

Published
2024
Full Text
View/download PDF

18. Eficacia de las infiltraciones con colágeno en el dolor pélvico causado por cicatrices de episiotomía y cesáreas. Ensayo clínico piloto aleatorizado

Author

Romero-Cullerés, G., Amela-Arévalo, A., Jané-Feixas, C., Vilaseca-Grané, A., Arnau, A., and Torà, N.

Abstract

El dolor pélvico es un síntoma frecuente de consulta en las unidades de rehabilitación de suelo pélvico. El objetivo de este estudio fue evaluar la eficacia de las infiltraciones con colágeno en el dolor y el aspecto de las cicatrices de desgarros perineales, episiotomías y/o cesáreas.

Published
2022
Full Text
View/download PDF

21. PD48-02 FIRST SAFETY AND EFFICACY RESULTS OF THE TAR-210 ERDAFITINIB INTRAVESICAL DELIVERY SYSTEM IN PATIENTS WITH NON–MUSCLE-INVASIVE BLADDER CANCER WITH SELECT FGFR ALTERATIONS.

Author

Vilaseca, Antoni, Jayram, Gautam, Raventos, Carles, Shore, Neal D., Zainfeld, Daniel, Kang, Taek Won, Ku, Ja Hyeon, Meeks, Joshua, Faba, Oscar Rodriguez, Roghmann, Florian, Daneshmand, Siamak, Beeharry, Neil, Cost, Carrye R., Kalota, Anna, Lauring, Josh, Peterson, Michelle R., Quiroz, Michelle, Stone, Nicole L., Zhu, Wei, and Ramos, Felix Gurrero

Subjects
NON-muscle invasive bladder cancer, BLADDER cancer, BCG immunotherapy
Published
2024
Full Text
View/download PDF

22. PD34-02 UTILITY OF INTRAVENOUS INDOCYANINE GREEN TO EVALUATE DISTAL URETERAL VASCULARITY DURING ROBOT-ASSISTED RADICAL CYSTECTOMY WITH INTRACORPOREAL URINARY DIVERSION.

Author

Carbonell, Enric, Muní, Maria, Martínez, Carmen, Alfambra, Héctor, Pagès, Rita, Villalba, Eric, Peradejordi, Mònica, Tello, Alberto, Mercader, Clàudia, Sierra, Alba, Vilaseca, Antoni, Ribal, María José, Alcaraz, Antonio, Musquera, Mireia, and Martos, Raúl

Subjects
URINARY diversion, INDOCYANINE green, CYSTECTOMY, SURGICAL robots, NEOADJUVANT chemotherapy
Published
2024
Full Text
View/download PDF

23. Functional analysis of TLK2variants and their proximal interactomes implicates impaired kinase activity and chromatin maintenance defects in their pathogenesis

Author

Pavinato, Lisa, Villamor-Payà, Marina, Sanchiz-Calvo, Maria, Andreoli, Cristina, Gay, Marina, Vilaseca, Marta, Arauz-Garofalo, Gianluca, Ciolfi, Andrea, Bruselles, Alessandro, Pippucci, Tommaso, Prota, Valentina, Carli, Diana, Giorgio, Elisa, Radio, Francesca Clementina, Antona, Vincenzo, Giuffrè, Mario, Ranguin, Kara, Colson, Cindy, De Rubeis, Silvia, Dimartino, Paola, Buxbaum, Joseph D, Ferrero, Giovanni Battista, Tartaglia, Marco, Martinelli, Simone, Stracker, Travis H, and Brusco, Alfredo

Abstract

IntroductionThe Tousled-like kinases 1 and 2 (TLK1 and TLK2) are involved in many fundamental processes, including DNA replication, cell cycle checkpoint recovery and chromatin remodelling. Mutations in TLK2were recently associated with ‘Mental Retardation Autosomal Dominant 57’ (MRD57, MIM# 618050), a neurodevelopmental disorder characterised by a highly variable phenotype, including mild-to-moderate intellectual disability, behavioural abnormalities, facial dysmorphisms, microcephaly, epilepsy and skeletal anomalies.MethodsWe re-evaluate whole exome sequencing and array-CGH data from a large cohort of patients affected by neurodevelopmental disorders. Using spatial proteomics (BioID) and single-cell gel electrophoresis, we investigated the proximity interaction landscape of TLK2and analysed the effects of p.(Asp551Gly) and a previously reported missense variant (c.1850C>T; p.(Ser617Leu)) on TLK2 interactions, localisation and activity.ResultsWe identified three new unrelated MRD57 families. Two were sporadic and caused by a missense change (c.1652A>G; p.(Asp551Gly)) or a 39 kb deletion encompassing TLK2, and one was familial with three affected siblings who inherited a nonsense change from an affected mother (c.1423G>T; p.(Glu475Ter)). The clinical phenotypes were consistent with those of previously reported cases. The tested mutations strongly impaired TLK2kinase activity. Proximal interactions between TLK2 and other factors implicated in neurological disorders, including CHD7, CHD8, BRD4 and NACC1, were identified. Finally, we demonstrated a more relaxed chromatin state in lymphoblastoid cells harbouring the p.(Asp551Gly) variant compared with control cells, conferring susceptibility to DNA damage.ConclusionOur study identified novel TLK2pathogenic variants, confirming and further expanding the MRD57-related phenotype. The molecular characterisation of missense variants increases our knowledge about TLK2 function and provides new insights into its role in neurodevelopmental disorders.

Published
2022
Full Text
View/download PDF

27. Rituximab Maintenance (RM) after First-Line (1L) Treatment Is Associated with a Lower Risk of Early-POD in Patients with Mantle Cell Lymphoma (MCL)

Author

Cabirta, Alba, Abrisqueta, Pau, Navarro Garcés, Víctor, Canelo-Vilaseca, Marta, Gomez-Rosa, Marina, Lopez García, Alberto, García, Tomas, De la Cruz, Fatima, Sancho, Juan-Manuel, Rios Herranz, Eduardo, Cordoba, Raul, Serna, Angel, Jiménez, Moraima, Bobillo, Sabela, Julia, Marta, Carpio, Cecilia, Iacoboni, Gloria, Gallur, Laura, Castellvi, Josep, Bosch, Francesc, and Marin-Niebla, Ana

Published
2022
Full Text
View/download PDF

28. Rituximab Maintenance (RM) after First-Line (1L) Treatment Is Associated with a Lower Risk of Early-POD in Patients with Mantle Cell Lymphoma (MCL)

Author

Cabirta, Alba, Abrisqueta, Pau, Navarro Garcés, Víctor, Canelo-Vilaseca, Marta, Gomez-Rosa, Marina, Lopez García, Alberto, García, Tomas, De la Cruz, Fatima, Sancho, Juan-Manuel, Rios Herranz, Eduardo, Cordoba, Raul, Serna, Angel, Jiménez, Moraima, Bobillo, Sabela, Julia, Marta, Carpio, Cecilia, Iacoboni, Gloria, Gallur, Laura, Castellvi, Josep, Bosch, Francesc, and Marin-Niebla, Ana

Published
2022
Full Text
View/download PDF

29. Clinical characteristics and outcomes of invasively ventilated patients with COVID-19 in Argentina (SATICOVID): a prospective, multicentre cohort study

Author

Estenssoro, Elisa, Loudet, Cecilia I, Ríos, Fernando G, Kanoore Edul, Vanina S, Plotnikow, Gustavo, Andrian, Macarena, Romero, Ignacio, Piezny, Damián, Bezzi, Marco, Mandich, Verónica, Groer, Carla, Torres, Sebastián, Orlandi, Cristina, Rubatto Birri, Paolo N, Valenti, María F, Cunto, Eleonora, Sáenz, María G, Tiribelli, Norberto, Aphalo, Vanina, Reina, Rosa, Dubin, Arnaldo, Estenssoro, E, Dubin, A, Loudet, C I, Ríos, F, Kanoore Edul, V S, Plotnikow, G, Reina, R, Andrian, M, Ivacachi, J, Romero, I, Garay, C, Piezny, D, Sagardía, J, Bezzi, M, Borello, S, Mandich, V, Chiacchiara, D, Groer, C, García Almirón, C, Kovac, A, Torres, S, Cesio, C, Orlandi, C, Hernández, R, Rubatto Birri, P N, Mugno, M, Valenti, M F, Gómez, R A, Cunto, E, Chediack, V, Sáenz, M G, Marchena, C, Tiribelli, N, Guaymas, M, Aphalo, V, Vázquez, D, Saad, Y, Sánchez, D, Iglesias, F, Casteluccio, P, Lattanzio, B, Eiguren, S, Noval, D, Fredes, S, Izzo, G C, Cabrera, H, Pozo, M O, Sac, S, Tornatore, N, Sakugawa, J, Villafañe, C, Di Sibio, A, Maskin, P, Rodríguez, P, Nihany, N, Mogadouro, M, Pálizas (h), F, Cornú, E, Esperatti, M, Pintos, J M, Badariotti, G, Echevarría, G, Mazzola, A M, Giuggia, C, Dargains, N, Turano, A, Pugliese, F, Zec Baskarad, M J, Chamadoira, M, Medina, J C, Búsico, M, Villarejo, F, Collazos, H, Huanca, T, Pendino, J C, Talamonti, L, Skrzypiec, F, Tascón, C, Genovese, G, Alul, H, Zavattieri, A, Herrera, A J, Rosales, N, Quintana, M G, Risso Vazquez, A, Lugaro, M, Díaz Rousseaux, E, Falcone, M, Kurban, F, Cini, M, Zakalik, G, Pellegrini, C, Fernández, G, Sottile, J P, Barrios, S, Hamada, O, Mendiluce, V, Villalba, D, Sacco, F, Mezzina, V, Servin, C, Quinteros, M, Nuñez, H, Campassi, M L, Banegas, D, Balasini, C, Leiva, V, Maicol, F, Domeniconi, G, Vilaseca, V, Barrientos, A, Larocca, F, Kumar, L, Luna, R, Deheza Lonardi, M, Oholeguy, A, Carnero Echegaray, J, Marazzi, C, Helca Regis, P, Rópolo, F, Bobadilla, A, Thomas, V, Funes Nelson, N, Villavicencio, C, Machare, P, Aramayo, N, González, C, Ferriccioni, M, and Bergesio, J

Abstract

Although COVID-19 has greatly affected many low-income and middle-income countries, detailed information about patients admitted to the intensive care unit (ICU) is still scarce. Our aim was to examine ventilation characteristics and outcomes in invasively ventilated patients with COVID-19 in Argentina, an upper middle-income country.

Published
2021
Full Text
View/download PDF

31. Calsyntenin‐1 is a cerebrospinal fluid marker of frontotemporal dementia‐related synapse degeneration.

Author

Belbin, Olivia, Irwin, David J., Alcolea, Daniel, Illán‐Gala, Ignacio, Santos‐Santos, Miguel A, McMillan, Corey T., Dolcet, Sonia Sirisi, Dols‐Icardo, Oriol, Cervantes‐González, Alba, Querol‐Vilaseca, Marta, Blesa, Rafael, Fortea, Juan, Lee, Eddie B., Trojanowski, John Q., Grossman, Murray, and Lleó, Alberto

Abstract

Background: Frontotemporal dementia (FTD) clinical diagnosis is challenged by the variable correspondence between the clinical syndrome and underlying neuropathological changes, the phenotypic overlap with Alzheimer's disease (AD) and the lack of pathophysiologic diagnostic biomarkers. As synapse degeneration is an early event in pathological frontotemporal lobar degeneration (FTLD), a surrogate marker of synapse loss could aid the early diagnosis of FTD. The aim of this study was to evaluate the diagnostic performance of a panel of 9 synaptic proteins in cerebrospinal fluid (CSF) for FTLD in a neuropathological cohort. Method: We included cognitively normal controls (n=35, 69 years+/‐7) and patients with neuropathological confirmation of FTLD (n=49, mean age‐at‐CSF 67 years+/‐10) or AD (n=25, 73 years+/‐6) from the Penn FTD Center. Subsets of the FTLD group included FTLD‐TDP (n=25) and FTLD‐Tau (n=24) neuropathological subtypes and "pure FTLD" (neurofibrillary tangle score of B0/B1 according to the NIA‐AA classification; n=39). We quantified the synaptic panel by targeted mass spectrometry using isotopically‐labeled proteotypic peptides as internal standards. We used linear regression with Dunnett's post‐hoc tests to compare group differences, receiver‐operating characteristic curves to assess diagnostic accuracy (AUC) and linear regression adjusting for age‐at‐death and sex to assess the association with tau burden. Result: Of the 9 synaptic proteins, CSF Calsyntenin‐1 showed the strongest association with disease etiology (r2=.12, p=.0006). Calsyntenin‐1 was lower in FTLD compared to controls (p=.03) and AD (p=.0008), particularly in "pure FTLD" (p=.02 vs controls, p=.0004 vs AD). Calsyntenin‐1 levels were comparable between AD and controls (p=.33) and between neuropathological FTLD subtypes (p=.66). Calsyntenin‐1 did not correlate with age‐at‐CSF analysis in controls (p=.74), FTLD (p=.07) or AD (p=.40). Calsyntenin‐1 showed the best diagnostic accuracy for differentiating FTLD from AD (AUC=73.4%) and showed similar accuracy in "pure FTLD" (AUC=75.7%) and in FTLD‐TDP (AUC=76.0%) and FTLD‐Tau (AUC=70.4%). Calsyntenin‐1 directly correlated with global pathological tau burden in FTLD (r2=.22; p=0.005) and in "pure FTLD" (r2=.17; p=0.02). Conclusion: Low CSF levels of the post‐synaptic modulator, Calsyntenin‐1, is specific to FTLD, particularly in cases with little or no tau pathology and could aid the early diagnosis of FTD and the differential diagnosis from AD and other tauopathies. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

34. RECOMENDACIONES ACTUALIZADAS PARA PROFILAXIS DE LA ENFERMEDAD TROMBOEMBÓLICA VENOSA EN ARGENTINA.

Author

VAZQUEZ, FERNANDO J., KORIN, JORGE, BALDESSARI, ENRIQUE M., CAPPARELLI, FEDERICO J., GUTIERREZ, PAULA, PALE, CARLOS, BOCANEGRA, FLORENCIA, GRAND, BEATRIZ, VILASECA, ALICIA, PENCHASKY, DIANA, GONZALEZ ALCANTARA, MARIA MONICA, SOL PRÉMOLI, MARÍA, TABARES, ALDO, WAINSZTEIN, NESTOR, ODETTO, DIEGO, VACCARO, CARLOS, MARTINEZ AQUINO, ELENO, CUMPIAN, OLGA, FALABELLA, VERÓNICA, and ANTUEL GARCÍA, SANTIAGO

Abstract

Copyright of Medicina (Buenos Aires) is the property of Medicina (Buenos Aires) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2020

35. Patterns of infection and infectious-related mortality in patients receiving post-transplant high dose cyclophosphamide as graft-versus-host-disease prophylaxis: impact of HLA donor matching

Author

Irene, García-Cadenas, Albert, Esquirol, Anna, Bosch-Vilaseca, Rahinatu, Awol, Silvana, Novelli, Silvana, Saavedra, Ana, Garrido, Jordi, López, Carolina, Caballero Ana, Miquel, Granell, Carolina, Moreno, Javier, Briones, Jorge, Sierra, and Rodrigo, Martino

Abstract

Post-transplant cyclophosphamide (PTCy) has become a promising option after allo-SCT, but infections may be more common than in traditional protocols. We herein report 117 consecutive adults who received PTCy-based alloSCT in our hospital: HaploSCT (34%), MRD (19%), and VUD (47%), respectively. The 18-month incidence of severe bacterial, viral, and IFI was 56%, 69%, and 8.7%, without differences between donor type, except for CMV infection and viral hemorrhagic cystitis, which had a higher incidence in the haploSCT cohort (58% vs. 43% and 30% vs. 8% on day +90, p< 0.05). Late infections by conventional respiratory viruses were common in all groups [33/87 (38%)]. The 2-year survival was 72% and did not differ by donor type. IRM at day 30, day 100, and 18 months was 1.7%, 4.4%, and 12%, without differences by donor type (p= 0.7). The primary cause of IRM was bacterial infection (42%). Grade 2–4 acute GvHD was the only independent predictor of IRM. Donor type had no impact on IRM or on survival. In our study, severe infections were common in all donor types using PTCy, with higher rates of early post-engraftment CMV-I and viral HC in haploSCT recipients, although lethal infections were uncommon and similar in all donor types.

Published
2021
Full Text
View/download PDF

38. Global multi-stakeholder endorsement of the MAFLD definition

Author

Méndez-Sánchez, Nahum, Bugianesi, Elisabetta, Gish, Robert G, Lammert, Frank, Tilg, Herbert, Nguyen, Mindie H, Sarin, Shiv K, Fabrellas, Núria, Zelber-Sagi, Shira, Fan, Jian-Gao, Shiha, Gamal, Targher, Giovanni, Zheng, Ming-Hua, Chan, Wah-Kheong, Vinker, Shlomo, Kawaguchi, Takumi, Castera, Laurent, Yilmaz, Yusuf, Korenjak, Marko, Spearman, C Wendy, Ungan, Mehmet, Palmer, Melissa, El-Shabrawi, Mortada, Gruss, Hans-Juergen, Dufour, Jean-François, Dhawan, Anil, Wedemeyer, Heiner, George, Jacob, Valenti, Luca, Fouad, Yasser, Romero‐Gomez, Manuel, Eslam, Mohammed, Abate, Maria Lorena, Abbas, Bahaa, Abbassy, Ahmed Amr, Abd El Ghany, Waleed, Abd Elkhalek, Amira, Abd ElMajeed, Emad, Abdalgaber, Mohammad, AbdAllah, Mohamed, Abdallah, Marwa, Abdallah, Nourhan, Abdelaleem, Shereen, Abdelghani, Yasser, Abdelghany, Wael, Abdelhalim, Safaa Mohamed, Abdelhamid, Wafaa, Abdelhamid, Nehal, Abdelkader, Nadia A., Abdelkreem, Elsayed, Abdelmohsen, Aly Mohamed, Abdelrahman, Awny Ali, Abd-elsalam, Sherief M, Abdeltawab, Doaa, Abduh, Abdulbaset, Abdulhakam, Nada, Abdulla, Maheeba, Abedpoor, Navid, Abenavoli, Ludovico, Åberg, Fredrik, Ablack, Omala, Abo elftouh, Mostafa, Abo-Amer, Yousry Esam-Eldin, Aboubkr, Ashraf, Aboud, Alaa, Abouelnaga, Amr M., Aboufarrag, Galal A., Aboutaleb, Ashraf, Abundis, Leticia, Adalı, Gupse, Adames, Enrique, Adams, Leon, Adda, Danjuma, Adel, Noor, Adel, Nada, Adel Sayed, Muhammad, Afaa, Taiba Jibril, Afredj, Nawal, Aghayeva, Gulnara, Aghemo, Alessio, Aguilar-Salinas, Carlos A., Ahlenstiel, Golo, Ahmady, Walid, Ahmed, Wafaa, Ahmed, Amira, Ahmed, Samah Nasser, Ahmed, Heba Mostafa, Ahmed, Rasha, Aigner, Elmar, Akarsu, Mesut, Akroush, Maisam, Akyuz, Umit, Al Mahtab, Mamun, Al Qadiri, Tahani, Al Rawahi, Yusriya, AL rubaee, Razzaq, Al Saffar, Muna, Alam, Shahinul, Al-Ani, Zaid, Albillos, Agustín, Alboraie, Mohamed, Al-Busafi, Said, Al-Emam, Mohamed, Alharthi, Jawaher, Ali, Kareem, Ali, Basma Abdelmoez, Ali, Mohammad, Ali, Raja Affendi Raja, Alisi, Anna, AL-Khafaji, Ali Raad, Alkhatry, Maryam, Aller, Rocio, Almansoury, Yahya, Al-Naamani, Khalid, Alnakeeb, Alaa, Alonso, Anna, Alqahtani, Saleh A., Alrabadi, Leina, Alswat, Khalid, Altaher, Mahir, Altamimi, Turki, Altamirano, Jose, Alvares-da-Silva, Mario R., Aly, Elsragy Adel M., Alzahaby, Amgad, Alzamzamy, Ahmed, Amano, Keisuke, Amer, Maysa A., Amin, Mona A., Amin, Sayed A., Amir, Ashraf A., Ampuero, Javier, Anas, Noha, Andreone, Pietro, Andriamandimby, Soa Fy, Anees, Mahmoud, Angela, Peltec, Antonios, Manal, Arafat, Wael, Araya, Jose Moreno, Armendariz-Borunda, Juan, Armstrong, Matthew J., Ashktorab, Hassan, Aspichueta, Patricia, Assal, Fathia, Atef, Mira, Attia, Dina, Atwa, Hoda, Awad, Reham, Awad, Mohyeldeen Abd Elaziz, Awny, Sally, Awolowo, Obafemi, Awuku, Yaw Asante, Ayada, Ibrahim, Aye, Than Than, Ayman, Sherif, Ayman, Hedy, Ayoub, Hesham, Azmy, Hosny M., Babaran, Romiro P., Badreldin, Omneya, Badry, Ahmed, Bahçecioğlu, İbrahim Halil, Bahour, Amira, Bai, Jiajia, Balaban, Yasemin, Balasubramanyam, Muthuswamy, Bamakhrama, Khaled, Banales, Jesus M, Bangaru, Babu, Bao, Jianfeng, Barahona, Jorge Suazo, Barakat, Salma, Barbalho, Sandra Maria, Barbra, Bikwa, Barranco, Beatriz, Barrera, Francisco, Baumann, Ulrich, Bazeed, Shamardan, Bech, Eva, Benayad, Aourarh, Benesic, Andreas, Bernstein, David, Bessone, Fernando, Birney, Susie, Bisseye, Cyrille, Blake, Martin, Bobat, Bilal, Bonfrate, Leonilde, Bordin, Dmitry S, Bosques-Padilla, Francisco, Boursier, Jerome, Boushab, Boushab Mohamed, Bowen, David, Bravo, Patricia Medina, Brennan, Paul N, Bright, Bisi, Broekaert, Ilse, Buque, Xabier, Burgos-Santamaría, Diego, Burman, Julio, Busetto, Luca, Byrne, Chris D., Cabral-Prodigalidad, Patricia Anne I., Cabrera-Alvarez, Guillermo, Cai, Wei, Cainelli, Francesca, Caliskan, Ali Riza, Canbay, Ali, Cano-Contreras, Ana, Cao, Hai-Xia, Cao, Zhujun, Carrion, Andres, Carubbi, Francesca, Casanovas, Teresa, Castellanos Fernández, Marlen Ivón, Chai, Jin, Chan, Siew Pheng, Charatcharoenwitthaya, Phunchai, Chavez-Tapia, Norberto, Chayama, Kazuaki, Chen, Jinjun, Chen, Lin, Chen, Zhong-Wei, Chen, Huiting, Chen, Sui-Dan, Chen, Qiang, Chen, Yaxi, Chen, Gang, Chen, En-Quang, Chen, Fei, Chen, Fei, Chen, Pei-Jer, Cheng, Robert, Cheng, Wendy, Chieh, Jack Tan Wei, Chokr, Imad, Cholongitas, Evangelos, Choudhury, Ashok, Chowdhury, Abhijit, Chukwudike, Evaristus Sunday, Ciardullo, Stefano, Clayton, Michelle, Clement, Karine, Cloa, Marie Michelle, Coccia, Cecilia, Collazos, Cristina, Colombo, Massimo, Cosar, Arif Mansur, Cotrim, Helma Pinchemel, Couillerot, Joris, Coulibaly, Alioune, Crespo, Gonzalo, Crespo, Javier, Cruells, Maria, Cua, Ian Homer Y., Dabbous, Hesham K., Dalekos, George N, D'Alia, Patricia, Dan, Li, Dao, Viet Hang, Darwish, Mostafa, Datz, Christian, Davalos-Moscol, Milagros B, Dawoud, Heba, de Careaga, Blanca Olaechea, de Knegt, Robert, de Ledinghen, Victor, de Silva, Janaka, Debzi, Nabil, Decraecker, Marie, Del Pozo, Elvira, Delgado, Teresa C, Delgado-Blanco, Manuel, Dembiński, Łukasz, Depina, Adilson, Derbala, Moutaz, Desalegn, Hailemichael, Desbois-Mouthon, Christèle, Desoky, Mahmoud, Dev, Anouk, Di Ciaula, Agostino, Diago, Moisés, Diallo, Ibrahima, Díaz, Luis Antonio, Dirchwolf, Melisa, Dongiovanni, Paola, Dorofeyev, Andrriy, Dou, Xiaoguang, Douglas, Mark W., Doulberis, Michael, Dovia, Cecil K., Doyle, Adam, Dragojević, Ivana, Drenth, Joost PH, Duan, Xuefei, Dulskas, Audrius, Dumitrascu, Dan L, Duncan, Oliver, Dusabejambo, Vincent, Dwawhi, Rev. Shem N.A., Eiketsu, Sho, El Amrousy, Doaa, El Deeb, Ahmed, El Deriny, Ghada, El Din, Hesham Salah, El Kamshishy, Salwa, El Kassas, Mohamed, El Raziky, Maissa, Elagamy, Osama A, Elakel, Wafaa, Elalfy, Dina, Elaraby, Hanaa, ElAwady, Heba, Elbadawy, Reda, Eldash, Hanaa Hassan, Eldefrawy, Manal S., Elecharri, Carol Lezama, Elfaramawy, Amel, Elfatih, Mohammed, Elfiky, Mahmoud, Elgamsy, Mohamed, Elgendy, Mohamed, El-Guindi, Mohamed A., Elhussieny, Nagi, Eliwa, Ahmed Maher, Elkabbany, Zeineb, El-Khayat, Hesham, El-Koofy, Nehal M., Elmetwalli, Alaa, Elrabat, Amr, El-Raey, Fathiya, Elrashdy, Fatma, Elsahhar, Medhat, Elsaid, Esraa M., Elsayed, Shimaa, Elsayed, Hany, Elsayed, Aly, Elsayed, Amr M., Elsayed, Hamdy, El-Serafy, Magdy, Elsharkawy, Ahmed M., Elsheemy, Reem Yehia, Elshemy, Eman Elsayed, Elsherbini, Sara, Eltoukhy, Naglaa, Elwakil, Reda, Emad, Ola, Emad, Shaimaa, Embabi, Mohamed, Ergenç, Ilkay, Ermolova, Tatiana, Esmat, Gamal, Esmat, Doaa M., Estupiñan, Enrique Carrera, Ettair, Said, Eugen, Tcaciuc, Ezz-Eldin, Mohammed, Falcón, Lidia Patricia Valdivieso, Fan, Yu-Chen, Fandari, Samah, Farag, Mahmoud, Farahat, Taghreed Mohamed, Fares, Eman M., Fares, Michael, Fassio, Eduardo, Fathy, Hayam, Fathy, Dina, Fathy, Wael, Fayed, Soheir, Feng, Dan, Feng, Gong, Fernández-Bermejo, Miguel, Ferreira, Cristina Targa, Ferrer, Javier Díaz, Forbes, Alastair, Fouad, Rabab, Fouad, Hanan M., Frisch, Tove, Fujii, Hideki, Fukunaga, Shuhei, Fukunishi, Shinya, Fulya, Hacer, Furuhashi, Masato, Gaber, Yasmine, Galang, Augusto Jose G., Gallardo, Jacqueline Cordova, Galloso, Rocío, Gamal, Mahmoud, Gamal, Reham, Gamal, Hadeel, Gan, Jian, Ganbold, Anar, Gao, Xin, Garas, George, Garba, Tony, García-Cortes, Miren, García-Monzón, Carmelo, García-Samaniego, Javier, Gastaldelli, Amalia, Gatica, Manuel, Gatley, Elizabeth, Gegeshidze, Tamar, Geng, Bin, Ghazinyan, Hasmik, Ghoneem, Salma, Giacomelli, Luca, Giannelli, Gianluigi, Giannini, Edoardo G., Giefer, Matthew, Ginès, Pere, Girala, Marcos, Giraudi, Pablo J, Goh, George Boon-Bee, Gomaa, Ahmed Ali, Gong, Benbingdi, Gonzales, Dina Hilda C., Gonzalez, Humberto C., Gonzalez-Huezo, Maria Saraí, Graupera, Isabel, Grgurevic, Ivica, Grønbæk, Henning, Gu, Xuelian, Guan, Lin, Gueye, Ibrahima, Guingané, Alice Nanelin, Gul, Ozen Oz, Gul, Cuma Bulent, Guo, Qing, Gupta, Pramendra Prasad, Gurakar, Ahmet, Gutierrez, Juan Carlos Restrepo, Habib, Ghada, Hafez, Azaa, Hagman, Emilia, Halawa, Eman, Hamdy, Osama, Hamed, Abd Elkhalek, Hamed, Dina H., Hamid, Saeed, Hamoudi, Waseem, Han, Yu, Haridy, James, Haridy, Hanan, Harris, David C H Harris, Hart, Michael, Hasan, Fuad, Hashim, Almoutaz, Hassan, Israa, Hassan, Ayman, Hassan, Essam Ali, Hassan, Adel Ahmed, Hassan, Magda Shehata, Hassanin, Fetouh, Hassnine, Alshymaa, Haukeland, John Willy, Hawal, Amr Ismael M., He, Jinfan, He, Qiong, He, Yong, He, Fang-Ping, Hegazy, Mona, Hegazy, Adham, Henegil, Osama, Hernández, Nelia, Hernández-Guerra, Manuel, Higuera-de-la-Tijera, Fatima, Hindy, Ibrahim, Hirota, Keisuke, Ho, Lee Chi, Hodge, Alexander, Hosny, Mohamed, Hou, Xin, Huang, Jiao-Feng, Huang, Yan, Huang, Zhifeng, Huang, Yuan, Huang, Ang, Huang, Yuan, Huang, Xiao-Ping, Hui-ping, Sheng, Hunyady, Bela, Hussein, Mennatallah A., Hussein, Osama, Hussien, Shahinaz Mahmoud, Ibáñez-Samaniego, Luis, Ibdah, Jamal, Ibrahim, Luqman, Ibrahim, Miada, Ibrahim, Ibrahim, Icaza-Chávez, Maria E., Idelbi, Sahar, Idilman, Ramazan Idilman, Ikeda, Mayumi, Indolfi, Giuseppe, Invernizzi, Federica, Irshad, Iram, Isa, Hasan Mohamed Ali, Iskandar, Natacha Jreige, Ismaiel, Abdulrahman, Ismail, Mariam, Ismail, Zulkifli, Ismail, Faisal, Iwamoto, Hideki, Jack, Kathryn, Jacob, Rachael, Jafarov, Fuad, Jafri, Wasim, Jahshan, Helen, Jalal, Prasun K, Jancoriene, Ligita, Janicko, Martin, Jayasena, Hiruni, Jefferies, Meryem, Jha, Vivekanand, Ji, Fanpu, Ji, Yaqiu, Jia, Jidong, Jiang, Changtao, Jiang, Ni, Jiang, Zong-zhe, Jin, Xing, Jin, Yi, Jing, Xu, Jingyu, Qian, Jinjolava, Maia, Jong, FX Himawan Haryanto, Jucov, Alina, Julius, Ibecheole, Kaddah, Mona, Kamada, Yoshihiro, kamal, Abobakr, Kamal, Enas Mohamed, Kamel, Ashraf Sayed, Kao, Jia-Horng, Karin, Maja, Karlas, Thomas, Kashwaa, Mohammad, Katsidzira, Leolin, Kaya, Eda, Kayasseh, M.Azzam, Keenan, Bernadette, Keklikkiran, Caglayan, Keml, William, Khalaf, Deia K., Khalefa, Rofida, Khamis, Sherin, Khater, Doaa, khattab, Hamed, Khavkin, Anatoly, Khlynova, Olga, Khmis, Nabil, Kobyliak, Nazarii, Koffas, Apostolos, Koike, Kazuhiko, Kok, Kenneth Y.Y., Koller, Tomas, Komas, Narcisse Patrice, Korochanskaya, Nataliya V., Koulla, Yannoula, Koya, Shunji, Kraft, Colleen, Kraja, Bledar, Krawczyk, Marcin, Kuchay, Mohammad Shafi, Kulkarni, Anand V, Kumar, Ashish, Kumar, Manoj, Lakoh, Sulaiman, Lam, Philip, Lan, Ling, Lange, Naomi F., Lankarani, Kamran Bagheri, Lanthier, Nicolas, Lapshyna, Kateryna, Lashen, Sameh A., Laure, Konang Nguieguia Justine, Lazebnik, Leonid, Lebrec, Didier, Lee, Samuel S., Lee, Way Seah, Lee, Yeong Yeh, Leeming, Diana Julie, Leite, Nathalie Carvalho, Leon, Roberto, Lesmana, Cosmas Rinaldi Adithya, Li, Junfeng, Li, Qiong, Li, Jun, Li, Yang-Yang, Li, Yufang, Li, Lei, Li, Min, li, Yiling, Liang, Huiqing, Lijuan, Tang, Lim, Seng Gee, Lim, Lee-Ling, Lin, Shumei, Lin, Han-Chieh, Lin, Rita, Lithy, Rania, Liu, Yaru, Liu, Yuanyuan, Liu, Xin, Liu, Wen-Yue, Liu, Shourong, Liu, Ken, Liu, Tian, Lonardo, Amedeo, López, Mariana Bravo, López-Benages, Eva, Lopez-Jaramillo, Patricio, Lu, Huimin, Lu, Lun Gen, Lu, Yan, Lubel, John, Lui, Rashid, Lupasco, Iulianna, Luzina, Elena, Lv, Xiao-Hui, Lynch, Kate, Ma, Hong-Lei, Machado, Mariana Verdelho, Maduka, Nonso, Madzharova, Katerina, Magdaong, Russellini, Mahadeva, Sanjiv, Mahfouz, Amel, Mahmood, Nik Ritza Kosai Nik, Mahmoud, Eman, Mahrous, Mohamed, Maiwall, Rakhi, Majeed, Ammar, Majumdar, Avik, Mak, Loey, Maklouf, Madiha M, Malekzadeh, Reza, Mandato, Claudia, Mangia, Alessandra, Mann, Jake, Mansour, Hala Hussien, Mansouri, Abdellah, Mantovani, Alessandro, Mao, Jun qian, Maramag, Flor, Marchesini, Giulio, Marcus, Claude, Marinho, Rui António Rocha Tato, Martinez-Chantar, Maria L, Martins, Antonieta A. Soares, Marwan, Rana, Mason, Karen Frances, Masoud, Ghadeer, Massoud, Mohamed Naguib, Matamoros, Maria Amalia, Mateos, Rosa Martín, Mawed, Asmaa, Mbanya, Jean Claude, Mbendi, Charles, McColaugh, Lone, McLeod, Duncan, Medina, Juan Francisco Rivera, Megahed, Ahmed, Mehrez, Mai, Memon, Iqbal, Merat, Shahin, Mercado, Randy, Mesbah, Ahmed, Meskini, Taoufik, Metwally, Mayada, Metwaly, Rasha, Miao, Lei, Micah, Eileen, Miele, Luca, Milivojevic, Vladimir, Milovanovic, Tamara, Mina, Yvonne L., Mishkovik, Milan, Mishriki, Amal, Mitchell, Tim, Mohamed, Alshaimaa, Mohamed, Mona, Mohamed, Sofain, Mohammed, Shady, Mohammed, Ahmed, Mohan, Viswanathan, Mohie, Sara, Mokhtar, Aalaa, Moniem, Reham, Montilla, Mabel Segura, Morales, Jose Antonio Orozco, Morata, María María Sánchez, Moreno-Planas, Jose Maria, Morise, Silvia, Mosaad, Sherif, Moselhy, Mohamed, Mostafa, Alaa Mohamed, Mostafa, Ebraheem, Mouane, Nezha, Mousa, Nasser, Moustafa, Hamdy Mahfouz, Msherif, Abeer, Muller, Kate, Munoz, Christopher, Muñoz-Urribarri, Ana Beatriz, Murillo, Omar Alfaro, Mustapha, Feisul Idzwan, Muzurović, Emir, Nabil, Yehia, Nafady, Shaymaa, Nagamatsu, Ayu, Nakajima, Atsushi, Nakano, Dan, Nan, Yuemin, Nascimbeni, Fabio, Naseef, Mirella S., Nashat, Nagwa, Natalia, Taran, Negro, Francesco, Nersesov, Alexander V., Neuman, Manuela, Ng'wanasayi, Masolwa, Ni, Yan, Nicoll, Amanda, Niizeki, Takashi, Nikolova, Dafina, Ningning, Wang, Niriella, Madunil, Nogoibaeva, K.A, Nordien, Rozeena, O Sullivan, Catherine, O'Beirne, James, Obekpa, Solomon, Ocama, Ponsiano, Ochwoto, Missiani, Ogolodom, Michael Promise, Ojo, Olusegun, Okrostsvaridze, Nana, Oliveira, Claudia P., Omaña, Raul Contreras, Omar, Omneya M., Omar, Hanaa, Omar, Mabroka, Omran, Salma, Omran, Reham, Osman, Marian Muse, Owise, Nevin, Owusu-Ansah, Theobald, Padilla- Machaca, P. Martín, Palle, Sirish, Pan, Ziyan, Pan, Xiao-Yan, Pan, Qiuwei, Papaefthymiou, Apostolis, Paquissi, Feliciano Chanana, Par, Gabriella, Parkash, Arit, Payawal, Diana, Peltekian, Kevork M., Peng, Xuebin, Peng, Liang, Peng, Ying, Pengoria, Rahul, Perez, Martina, Pérez, José Luis, Pérez, Norma Marlene, Persico, Marcello, Pessoa, Mário Guimarães, Petta, Salvatore, Philip, Mathew, Plaz Torres, Maria Corina, Polavarapu, Naveen, Poniachik, Jaime, Portincasa, Piero, Pu, Chunwen, Pürnak, Tuğrul, Purwanto, Edhie, Qi, Xiaolong, Qi, Xingshun, Qian, Zibing, Qiang, Zhao, Qiao, Zengpei, Qiao, Liang, Queiroz, Alberto, Rabiee, Atoosa, Radwan, Manal, Rahetilahy, Alain Marcel, Ramadan, Yasmin, Ramadan, Dina, Ramli, Anis Safura, Ramm, Grant A., Ran, Ao, Rankovic, Ivan, RAO, Huiying, Raouf, Sara, Ray, Sayantan, Reau, Nancy, Refaat, Ahmed, Reiberger, Thomas, Remes-Troche, Jose M, Reyes, Eira Cerda, Richardson, Ben, Ridruejo, Ezequiel, Riestra Jimenez, Sergio, Rizk, Ibrahim, Roberts, Stuart, Roblero, Juan Pablo, Robles, Jorge Alberto Prado, Rockey, Don, Rodríguez, Manuel, Rodríguez Hernández, Heriberto, Román, Eva, Romeiro, Fernando Gomes, Romeo, Stefano, Rosales-Zabal, Jose Miguel, Roshdi, Georgina R., Rosso, Natalia, Ruf, Andres, Ruiz, Patricia Cordero, Runes, Nelia R., Ruzzenente, Andrea, Ryan, Marno, Saad, Ahmed, Sabbagh, Eman BE, Sabbah, Meriam, Saber, Shimaa, Sabrey, Reham, Sabry, Ramy, Saeed, Maysaa Abdallah, Said, Dina, Said, Ebada M, Sakr, Mohammad Amin, Salah, Yara, Salama, Rabab Maamoun, Salama, Asmaa, Saleh, Hussein, Saleh, Ahmed, Salem, Ahmed, Salem, Ahmed Thabet, Salifou, Alkassoum, Salih, Aso Faeq, Salman, Abdallah, Samouda, Hanen, Sanai, Faisal, Sánchez-Ávila, Juan Francisco, Sanker, Lakshumanan, Sano, Tomoya, Sanz, Miquel, Saparbu, Tobokalova, Sawhney, Rohit, Sayed, Fatma, Sayed, Sayed A., Sayed, Ashraf Othman, Sayed, Manar, Sebastiani, Giada, Secadas, Laura, Sediqi, Khawaja Qamaruddin, Seif, Sameh, Semida, Nady, Şenateş, Ebubekir, Serban, Elena Daniela, Serfaty, Lawrence, Seto, Wai-Kay, Sghaier, Ikram, Sha, Min, Shabaan, Hamada M., Shalaby, Lobna, Shaltout, Inass, Sharara, Ala I., Sharma, Vishal, Shawa, Isaac Thom, Shawkat, Ahmed, Shawky, Nehal, Shehata, Osama, Sheils, Sinead, Shewaye, Abate Bane, Shi, Guojun, Shi, Junping, Shimose, Shigeo, Shirono, Tomotake, Shou, Lan, Shrestha, Ananta, Shui, Guanghou, Sievert, William, Sigurdardottir, Solveig, Sira, Mostafa Mohamed, Siradj, Riyadh, Sison, Cecilia, Smyth, Linda, Soliman, Reham, Sollano, Jose D, Sombie, Roger, Sonderup, Mark, Sood, Siddharth, Soriano, German, Stedman, Catherine A M, Stefanyuk, Oksana, Štimac, Davor, Strasser, Simone, Strnad, Pavel, Stuart, Katherine, Su, Wen, Su, Minghua, Sumida, Yoshio, Sumie, Shuji, Sun, Dan-Qin, Sun, Jing, Suzuki, Hiroyuki, Svegliati-Baroni, Gianluca, Swar, Mohamed Osman, TAHARBOUCHT, S., Taher, Zenab, Takamura, Saori, Tan, Lin, Tan, Soek-Siam, Tanwandee, Tawesak, Tarek, Sara, Tatiana, Ghelimici, Tavaglione, Federica, Tecson, Gina Y., Tee, Hoi-Poh, Teschke, Rolf, Tharwat, Mostafa, Thong, Vo Duy, Thursz, Mark, Tine, Tulari, Tiribelli, Claudio, Tolmane, Ieva, Tong, Jing, Tongo, Marco, Torkie, Mamdouh, Torre, Aldo, Torres, Esther A, Trajkovska, Meri, Treeprasertsuk, Sombat, Tsutsumi, Tsubasa, Tu, Thomas, Tur, Josep A., Turan, Dilara, Turcan, Svetlana, Turkina, Svetlana, Tutar, Engin, Tzeuton, Christian, Ugiagbe, Rose, Uygun, Ahmet, Vacca, Michele, Vajro, Pietro, Van der Poorten, David, Van Kleef, Laurens A., Vashakidze, Eliza, Velazquez, Carlos Moctezuma, Velazquez, Mirtha Infante, Vento, Sandro, Verhoeven, Veronique, Vespasiani-Gentilucci, Umberto, Vethakkan, Shireene Ratna, Vilaseca, Josep, Vítek, Libor, Volkanovska, Ance, Wallace, Michael, Wan, Wang, Wang, Yan, Wang, Ying, Wang, Xiaolin, Wang, Xuemei, Wang, Chengyan, Wang, Chunjiong, Wang, Mingjie, Wangchuk, Pelden, Weltman, Martin, White, MaryFrances, Wiegand, Johannes, Wifi, Mohamed-Naguib, Wigg, Alan, Wilhelmi, Markus, William, Remon, Wittenburg, Henning, Wu, Shengjie, Wubeneh, Abdu Mohammed, Xia, Hongping, Xiao, Jian, Xiao, Xiao, Xiaofeng, Wang, Xiong, Wanyuan, Xu, Liang, Xu, Jie, Xu, Weiguo, Xu, Jing-Hang, Xu, Keshu, Xu, Yumin, Xu, Shi-Hao, Xu, Meng, Xu, Aimin, Xu, Chengfu, Yan, Hongmei, Yang, Jingyi, Yang, Rui-Xu, Yang, Yating, Yang, Qinhe, Yang, Naibin, Yao, Jia, Yara, Justine, Yaraş, Serkan, Yılmaz, Nimet, Younes, Ramy, younes, Huda, Young, Sona, Youssef, Farah, Yu, Yanyan, Yu, Ming-Lung, Yuan, Jing, Yue, Zhang, Yuen, Man-Fung, Yun, Wang, Yurukova, Nonka, Zakaria, Serag, Zaky, Samy, Zaldastanishvili, Maia, Zapata, Rodrigo, Zare, Nazanin, Zerem, Enver, Zeriban, Nema, Zeshuai, Xu, Zhang, Huijie, Zhang, Xuemei, Zhang, Yupei, Zhang, Wen-Hua, Zhang, Xuchen, Zhang, Yon-ping, Zhang, Yuexin, Zhang, Zhan-qing, Zhao, Jingmin, Zhao, Rong-Rong, Zhao, Hongwei, Zheng, Chao, Zheng, Yijie, Zheng, Ruidan, Zheng, Tian-Lei, Zheng, Kenneth, Zhou, Xi Qiao, Zhou, Yongjian, Zhou, Yu-Jie, Zhou, Hong, Zhou, Ling, Zhou, Yongning, Zhu, Long dong, Zhu, Yong Fen, Zhu, Yueyong, Zhu, Pei-Wu, Ziada, Ebtesam, Ziring, David, Ziyi, Li, Zou, Shanshan, Zou, Zhengsheng, Zou, Huaibin, and Zuart Ruiz, Roberto

Published
2022
Full Text
View/download PDF

39. Timing, Complications, and Safety of Tracheotomy in Critically Ill Patients With COVID-19

Author

Avilés-Jurado, Francesc Xavier, Prieto-Alhambra, Daniel, González-Sánchez, Nesly, de Ossó, José, Arancibia, Claudio, Rojas-Lechuga, María Jesús, Ruiz-Sevilla, Laura, Remacha, Joan, Sánchez, Irene, Lehrer-Coriat, Eduardo, López-Chacón, Mauricio, Langdon, Cristóbal, Guilemany, Josep María, Larrosa, Francisco, Alobid, Isam, Bernal-Sprekelsen, Manuel, Castro, Pedro, and Vilaseca, Isabel

Abstract

IMPORTANCE: The current coronavirus disease 2019 (COVID-19) pandemic has led to unprecedented needs for invasive ventilation, with 10% to 15% of intubated patients subsequently requiring tracheotomy. OBJECTIVE: To assess the complications, safety, and timing of tracheotomy performed for critically ill patients with COVID-19. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study assessed consecutive patients admitted to the intensive care unit (ICU) who had COVID-19 that required tracheotomy. Patients were recruited from March 16 to April 10, 2020, at a tertiary referral center. EXPOSURES: A surgical tracheotomy was performed for all patients following recommended criteria for use of personal protective equipment (PPE). MAIN OUTCOMES AND MEASURES: The number of subthyroid operations, the tracheal entrance protocol, and use of PPE. Infections among the surgeons were monitored weekly by reverse-transcriptase polymerase chain reaction of nasopharyngeal swab samples. Short-term complications, weaning, and the association of timing of tracheotomy (early [≤10 days] vs late [>10 days]) with total required days of invasive ventilation were assessed. RESULTS: A total of 50 patients (mean [SD] age, 63.8 [9.2] years; 33 [66%] male) participated in the study. All tracheotomies were performed at the bedside. The median time from intubation to tracheotomy was 9 days (interquartile range, 2-24 days). A subthyroid approach was completed for 46 patients (92%), and the tracheal protocol was adequately achieved for 40 patients (80%). Adequate PPE was used, with no infection among surgeons identified 4 weeks after the last tracheotomy. Postoperative complications were rare, with minor bleeding (in 6 patients [12%]) being the most common complication. The successful weaning rate was higher in the early tracheotomy group than in the late tracheotomy group (adjusted hazard ratio, 2.55; 95% CI, 0.96-6.75), but the difference was not statistically significant. There was less time of invasive mechanical ventilatory support with early tracheotomy compared with late tracheotomy (mean [SD], 18 [5.4] vs 22.3 [5.7] days). The reduction of invasive ventilatory support was achieved at the expense of the pretracheotomy period. CONCLUSIONS AND RELEVANCE: In this cohort study, with the use of a standardized protocol aimed at minimizing COVID-19 risks, bedside open tracheotomy was a safe procedure for patients and surgeons, with minimal complications. Timing of tracheotomy may be important in reducing time of invasive mechanical ventilation, with potential implications to intensive care unit availability during the COVID-19 pandemic.

Published
2021
Full Text
View/download PDF

40. Mejor separados (o «¡que les corten la cabeza! »).

Author

Vilaseca Llobet, Josep Maria

Abstract

Copyright of AMF: Actualización en Medicina de Familia is the property of Sociedad Espanola de Medicina en Familia y Comunitaria and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2023
Full Text
View/download PDF

42. Impacto de la anemia sobre la supervivencia de los pacientes intervenidos de cistectomía radical por tumor vesical

Author

Ferran-Carpintero, A., Domínguez-García, A., Muñoz-Rodríguez, J., Barquero-López, M., Prera-Vilaseca, Á., Bonfill-Abella, T., Gallardo-Díaz, E., Hannaoui-Hadi, N., García-Rojo, D., and Prats-López, J.

Abstract

Evaluar la prevalencia de anemia preoperatoria y su impacto sobre los resultados oncológicos de pacientes intervenidos de cistectomía radical (CR) por tumor vesical.

Published
2020
Full Text
View/download PDF

43. La endoscopia del sueño inducido

Author

Carrasco Llatas, Marina, Martínez Ruiz de Apodaca, Paula, Baptista Jardín, Peter, O’Connor Reina, Carlos, Plaza Mayor, Guillermo, Méndez-Benegassi Silva, Iván, Vicente González, Eugenio, Vilaseca González, Isabel, Navazo Egía, Ana Isabel, Samará Piñol, Laura, Álvarez García, Irene, Vila Martín, Javier, and Esteller Moré, Eduard

Abstract

Este documento pretende dar a conocer la endoscopia de sueño inducido entre los distintos especialistas que tratan a los pacientes con trastornos respiratorios del sueño y ser una guía para los especialistas que vayan a realizarla de modo que pueda ser reproducible.

Published
2020
Full Text
View/download PDF

44. Value of Partial Nephrectomy for Renal Cortical Tumors of cT2 or Greater Stage: A Risk-benefit Analysis of Renal Function Preservation Versus Increased Postoperative Morbidity

Author

Vilaseca, Antoni, Guglielmetti, Giuliano, Vertosick, Emily A., Sjoberg, Daniel D., Grasso, Angelica, Benfante, Nicole E., Nguyen, Daniel P., Corradi, Renato B., Coleman, Jonathan, Russo, Paul, Vickers, Andrew J., and Touijer, Karim A.

Abstract

Indications for partial nephrectomy (PN) have expanded to include larger tumors. Compared with radical nephrectomy (RN), PN reduces the risk of chronic kidney disease but is associated with higher morbidity.

Published
2020
Full Text
View/download PDF

45. Incorporating posttransplant cyclophosphamide-based prophylaxis as standard-of-care outside the haploidentical setting: challenges and review of the literature

Author

García-Cadenas, I., Awol, R., Esquirol, A., Saavedra, S., Bosch-Vilaseca, A., Novelli, S., Garrido, A., López, J., Granell, M., Moreno, C., Briones, J., Brunet, S., Sierra, J., and Martino, R.

Abstract

Posttransplant high-dose cyclophosphamide (PTCy) effectively prevents GvHD after haploidentical SCT. However, its use in HLA-matched SCT has been less explored. Fifty-six consecutive patients who underwent allo-SCT for hematological malignancies have been included in this prospective single-center protocol. Donors have been HLA-identical siblings, fully-matched unrelated or 1-allele-mismatched unrelated donors in 30%, 32%, and 37% of cases, respectively. Nine patients have received a TBI-containing MAC regimen, while the remaining (84%) received RIC platforms based on Fludarabine plus Busulfan/Melphalan. Due to the high graft failure (GF) rate (21%) in a preliminary analysis in the allo-RIC cohort (n= 29), protocol amendments have been implemented, with no further cases of GF after the introduction of mini-thiotepa (0/18). The overall incidence of grade II–IV acute GvHD is 24% (95% CI: 17–31%) with four steroid-refractory cases. Severe chronic GvHD has occurred in only 1 of 43 evaluable cases. The 1-year NRM and relapse are 18% (95% CI: 12–26%) and 30% (18–42%) and the OS and DFS are 78% and 64%, respectively. These outcomes support the feasibility of using PTCy as a SOC outside the haplo-setting, albeit mini-thiotepa (3 mg/kg) was incorporated in the standard allo-RIC platforms to prevent GF. Despite the limitations of a single-center experience and the short follow-up, these protocols show promising results with particular benefit in reducing the occurrence of moderate-to-severe GvHD.

Published
2020
Full Text
View/download PDF

46. Tumores glóticos precoces con afectación de la comisura anterior. Revisión bibliográfica y documento de consenso. Comisión de cabeza y cuello y base de cráneo. SEORL-CCC

Author

Porras Alonso, Eulalia, Vilaseca González, Isabel, García Teno, Miguel, Barberá Durbán, Rafael, Viscasillas Pallàs, Guillem, Sancho Mestre, Manuela, Rebollo Otal, Juan, Menoyo Bueno, Alicia, and Díaz de Cerio Canduela, Pedro

Abstract

La elección del tratamiento más adecuado en el cáncer glótico en estadio precoz con afectación de la comisura anterior sigue siendo controvertida. La complejidad en su manejo terapéutico está justificada por ser un significativo indicador pronóstico de control local, con un porcentaje de recidiva del 37%, por la dificultad en establecer la extensión tumoral con una infraestadificación que llega a alcanzar el 40%, y por la comparación de resultados en series formadas por tumores de diferente comportamiento evolutivo, como son T1a, T1b y T2a con afectación comisural. A estos datos se suma la complejidad del abordaje quirúrgico mediante microcirugía transoral con láser CO2que requiere habilidad quirúrgica, equipamiento adecuado y experiencia.

Published
2020
Full Text
View/download PDF

47. Characterization of Human Sperm Protamine Proteoforms through a Combination of Top-Down and Bottom-Up Mass Spectrometry Approaches

Author

Soler-Ventura, Ada, Gay, Marina, Jodar, Meritxell, Vilanova, Mar, Castillo, Judit, Arauz-Garofalo, Gianluca, Villarreal, Laura, Ballescà, Josep Lluís, Vilaseca, Marta, and Oliva, Rafael

Abstract

Protamine 1 (P1) and protamine 2 (P2) family are extremely basic, sperm-specific proteins, packing 85–95% of the paternal DNA. P1 is synthesized as a mature form, whereas P2 components (HP2, HP3, and HP4) arise from the proteolysis of the precursor (pre-P2). Due to the particular protamine physical–chemical properties, their identification by standardized bottom-up mass spectrometry (MS) strategies is not straightforward. Therefore, the aim of this study was to identify the sperm protamine proteoforms profile, including their post-translational modifications, in normozoospermic individuals using two complementary strategies, a top-down MS approach and a proteinase-K-digestion-based bottom-up MS approach. By top-down MS, described and novel truncated P1 and pre-P2 proteoforms were identified. Intact P1, pre-P2, and P2 mature proteoforms and their phosphorylation pattern were also detected. Additionally, a +61 Da modification in different proteoforms was observed. By the bottom-up MS approach, phosphorylated residues for pre-P2, as well as the new P2 isoform 2, which is not annotated in the UniProtKB database, were revealed. Implementing these strategies in comparative studies of different infertile phenotypes, together with the evaluation of P1/P2 and pre-P2/P2 MS-derived ratios, would permit determining specific alterations in the protamine proteoforms and elucidate the role of phosphorylation/dephosphorylation dynamics in male fertility.

Published
2020
Full Text
View/download PDF

48. Microplastics' emissions: Microfibers' detachment from textile garments.

Author

Belzagui, Francisco, Crespi, Martí, Álvarez, Antonio, Gutiérrez-Bouzán, Carmen, and Vilaseca, Mercedes

Subjects
MICROFIBERS, PLASTIC marine debris, DRINKING water, CLOTHING & dress, TEXTILES, POLLUTANTS
Abstract

Microplastics (synthetic polymers <5 mm) have been recently recognized as a big environmental concern, as their ubiquity is an undeniable fact. Their wide variety regarding shapes, sizes, and materials turn them into an intrinsically risky pollutant capable of causing several environmental impacts. Textile microfibers (MF) are a microplastic sub-group. These are mostly shed when a normal laundry of any garment takes place. Special attention has been put onto them, as high concentrations have been found in products for human consumption as shellfish and tap water. However, as there is no consensus on the methodologies to quantify and report the results of MFs detached from textile garments, the degree of similarity between published studies is very low. Hence, the aim of this research was to evaluate the microfibers' detachment rates of finished garments and to provide a set of comparable units to report the results. These were found to range between 175 and 560 MF/g or 30000–465000 MF/m2 of garment. In addition, there was a high correlation between the MF detachment and the textile article superficial density. Finally, our results were compared with a recent paper that estimated the annual mass flow of MFs to the oceans. This previous publication is 30 times higher when related to the mass but 40 times lower if related to the number of MFs. Image 1 • A reproducible method to quantify textile microfibers was developed. • Comprehensive and comparable units to present the results are recommended. • Microfibers have 2 different morphologies that give information about their detachment. • Mass flow of microfibers reaching the oceans might be lower than previously reported. • Number of microfibers reaching the oceans might be higher than previously reported. This work provides new insights with respect to microplastic pollution. It also establishes a method for the quantification of textile microfibers and recommends comprehensive and comparable units to be used when publishing the results. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

50. Parálisis de Bell y covid-19: estudio de cohortes de comparación histórica

Author

Arango, Natalia, Rojas-Lechuga, María Jesús, Chen, Jiwei, Larrosa, Francisco, Alegre, Berta, and Vilaseca, Isabel

Abstract

Durante la pandemia por SARS-CoV-2 se describieron episodios neurológicos inmunomediados en pacientes vacunados contra el virus o que habían superado la enfermedad. Dentro de ellos se encuentra la parálisis facial periférica idiopática o parálisis de Bell.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results